CN1775242A - Medicine composition with bacteria-inhibiting anti-inflammation function, its preparing method and use - Google Patents
Medicine composition with bacteria-inhibiting anti-inflammation function, its preparing method and use Download PDFInfo
- Publication number
- CN1775242A CN1775242A CN 200510123618 CN200510123618A CN1775242A CN 1775242 A CN1775242 A CN 1775242A CN 200510123618 CN200510123618 CN 200510123618 CN 200510123618 A CN200510123618 A CN 200510123618A CN 1775242 A CN1775242 A CN 1775242A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- herba
- extract
- herba houttuyniae
- diclipterae chinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine composition with the good action of inhibiting bacteria, resisting inglammation and resisting virus for curing the diseases of viral common cold, upper respiratory tract infection, epidemic parotitis and pneumonia, etc. Said medicine composition includes Chinese medicinal materials of dicliptera chinensis and houttuynia cordata. Besides, said invention also provides its preparation process and application method.
Description
Technical field
The invention belongs to the pharmaceutical technology field, be specifically related to a kind of pharmaceutical composition and preparation method thereof and purposes with bacteria-inhibiting anti-inflammation function, in particular, relate to a kind of by Herba Diclipterae Chinensis and Herba Houttuyniae compatibility, through extracting pharmaceutical composition that active component is prepared from and preparation method thereof and purposes.
Technical background
In today of antibiotic extensive use, viral disease has occupied the prostatitis of all infectious disease to the harm of human health.Therefore, seek and the exploitation toxic and side effects is little, antiviral drugs has crucial meaning safely and effectively.Chinese medicine has the not available advantage of many chemicalses, and effect is obvious.Therefore, from Chinese medicine, seek and develop new medicine and have vast market prospect with antivirus action.
Herba Diclipterae Chinensis is the dry herb of acanthaceous plant Herba Diclipterae Chinensis Dicliptera chinensis (L.) Ness, it is cool in nature, sweet in the mouth, light has heat-clearing and toxic substances removing, removing heat from blood, promotes the production of body fluid, diuresis, records in " Chinese pharmacopoeia version in 1977, be mainly used in cold, fever, the calentura macule, summer-heat excessive thirst, eye conjunctivitis, diseases such as laryngopharynx swelling and pain have curative effect preferably.The chemical constituent bibliographical information of Herba Diclipterae Chinensis is less, and by research, it mainly contains compositions such as flavone, polysaccharide, volatile oil and amino acids.
Herba Houttuyniae is Saururaceae plant Herba Houttuyniae (Houttuynia cordata Thunb), records in middle pharmacopeia.The traditional Chinese medical science is thought, the Herba Houttuyniae property and flavor of peppery and cold is gone into lung, Liver Channel, and heat-clearing and toxic substances removing is arranged, the row edema, and inducing diuresis for treating stranguria syndrome, the merit of the silt tissue regeneration promoting of dispelling is the key medicine of tcm clinical practice treatment lung abscess.Modern pharmacological research shows:
(1) Herba Houttuyniae is inhibited to multiple viruses such as Asia first type virus, influenza virus and hemorrhagic fever viruss;
(2) antibacterial action.Streptococcus pneumoniae, hemophilus influenza, staphylococcus aureus, Hemolytic streptococcus, diphtheria corynebacterium, gonococcus and micrococcus catarrhalis etc. all there is the obvious suppression effect;
(3) raise immunity.Radioactive leucocytes reduction there is protective effect, can strengthens macrophage function;
(4) antiallergic, antiasthmatic effect.Can antagonism histamine, good anti-allergic effects is arranged, in addition can the antagonism acetylcholine to the effect of airway smooth muscle.
Clinical each sharp inflammation treatment, amygdala inflammation, upper respiratory tract infection, bronchitis, pneumonia, the adnexitis etc. of being mainly used in of Herba Houttuyniae and Chinese patent medicine prepared therefrom.
Pharmacological effect based on Herba Houttuyniae is clear and definite, existing a plurality of products and patent are announced, as: it is raw material with Flos Lonicerae, Folium Isatidis, Herba Taraxaci, Herba Houttuyniae that patent application 00114303.4 discloses a kind of, by 1: 1: 1: the medicament that 1 weight proportion is made was used to suppress the cytopathy that human cytomegalic inclusion disease virus causes.
It is raw material with Flos Lonicerae, Folium Isatidis, Herba Taraxaci, Herba Houttuyniae that patent application 00114304.2 discloses a kind of, by 1: 1: 1: the medicament that 1 weight proportion is made, have heat-clearing and toxic substances removing, lung heat clearing removing heat from blood, detumescence and apocenosis, diuresis inducing function, pharmacodynamic study prove its can be antibiotic, antiviral, antiendotoxin, analgesic, antiinflammatory, and can regulate immunologic function.
The volatile oil component that above-mentioned patent is all at first extracted in the Herba Houttuyniae is standby, then Flos Lonicerae, Folium Isatidis and Herba Taraxaci water decoction-alcohol sedimentation are obtained effective ingredient, make granule according to the conventional method on the pharmaceutics, with Herba Houttuyniae volatile oil evenly be sprayed at granule, sealing obtains product.
But in actual production and application, find, above-mentioned prescription complexity, difficulty is controlled conformity of production, cost is relatively also high.
In available data, all do not relate to independent use Herba Diclipterae Chinensis and Herba Houttuyniae compatibility, extract, the preparation new drug.The inventor is in conjunction with studying discovery for a long period of time, and with Herba Diclipterae Chinensis and Herba Houttuyniae compatibility, prescription is simple, curative effect is clear and definite.
Summary of the invention
At above the deficiencies in the prior art, research worker of the present invention is according to the physicochemical property of the contained chemical constituent of above-mentioned two flavor medical materials, on the basis of repetition test research, preparing with Herba Diclipterae Chinensis and Herba Houttuyniae is the new Pharmaceutical composition of raw medicinal material, and pharmaceutical composition of the present invention has excellent antibiotic, antiinflammatory, antivirus action.
The objective of the invention is to disclose a kind of pharmaceutical composition with bacteria-inhibiting anti-inflammation function, a kind of specifically by Herba Diclipterae Chinensis and Herba Houttuyniae compatibility, the pharmaceutical composition for preparing through effective component extracting.
Another object of the present invention also is to provide the preparation method of aforementioned pharmaceutical compositions.
Another purpose of the present invention is to provide antibiotic, antiinflammatory, the anti-viral uses of above-mentioned composition, specifically is the purposes aspect disease medicines such as preparation treatment viral influenza, upper respiratory tract infection mumps, pneumonia.
Pharmaceutical composition of the present invention, its raw medicinal material are Herba Diclipterae Chinensis and Herba Houttuyniae, and both share and can play good synergistic effects.
Pharmaceutical composition of the present invention, its raw medicinal material weight percentage is: Herba Diclipterae Chinensis 50%-90%, Herba Houttuyniae 10%-50%.
Pharmaceutical composition of the present invention, its raw medicinal material weight percentage is preferably: Herba Diclipterae Chinensis 60%-70%, Herba Houttuyniae 30%-40%.
Pharmaceutical composition of the present invention, its raw medicinal material weight percentage most preferably is: Herba Diclipterae Chinensis 62.5%, Herba Houttuyniae 37.5%.
Pharmaceutical composition of the present invention can prepare by the following method:
Volatile oil that will extract from Herba Diclipterae Chinensis, Herba Houttuyniae and water extract add the corresponding medicinal adjuvant and can make corresponding dosage forms as raw material.
Specifically, pharmaceutical composition of the present invention can prepare by the following method:
(1) Herba Diclipterae Chinensis, Herba Houttuyniae are pulverized, adopted steam distillation or supercritical liquid extraction technique to extract, get extract A;
(2) with above-mentioned medicinal residues with water boiling and extraction 1-2 time, merge extractive liquid, filters, filtrate decompression is concentrated into the 1/4-1/2 that is equivalent to the raw medicinal herbs amount, under agitation adds ethanol and makes and contain the alcohol amount and reach 50%-90%, leaves standstill, and filters, the filtrate concentrate drying gets extract B.
(3) extract A and extract B are merged, add the corresponding medicinal adjuvant, make corresponding preparation.
Pharmaceutical composition of the present invention can be prepared into the available dosage form on the various pharmaceuticss, as tablet, capsule, granule, oral liquid, injection with small volume, high-capacity injection, injectable powder, lyophilized injectable powder; Preferred injection with small volume.
The various dosage forms of pharmaceutical composition of the present invention can be according to the conventional production method preparation of pharmaceutical field.
Pharmaceutical composition of the present invention can be prepared into the available dosage form on the various pharmaceuticss, therefore can use said composition also can contain one or more adjuvant; Such as sodium chloride, starch, Pulvis Talci and magnesium stearate etc., the acceptable adjuvant of pharmaceutical field.
Pharmaceutical composition of the present invention has excellent antibiotic, antiinflammatory, antivirus action, can be used for treating diseases such as viral influenza, upper respiratory tract infection, mumps, pneumonia.
Research worker of the present invention is tested in a large number, and the optimal proportion of testing Herba Diclipterae Chinensis and Herba Houttuyniae in the pharmaceutical composition of the present invention with reference to the pharmacological effect of embodiment has carried out preferably.Experimental result sees Table 1.
Table 1 set of dispense compares optimization experiment
| The experiment number | Herba Diclipterae Chinensis: Herba Houttuyniae (%) | Pharmacological action |
| 1 2 3 4 5 6 7 8 | 0∶100 10∶90 20∶80 30∶70 40∶60 50∶50 60∶40 70∶30 | ± + + + + ++ +++ +++ |
| 9 10 11 | 80∶20 90∶10 100∶0 | ++ ++ ± |
Annotate: ± expression pharmacological action is poor; + expression pharmacological action is general; ++ the expression pharmacological action is better; +++expression pharmacological action is better.
By above-mentioned experimental result as can be seen, Herba Diclipterae Chinensis and Herba Houttuyniae unite use (2-10 number experiment) than single with Herba Diclipterae Chinensis (No. 11 experiments) and single good effect with Herba Houttuyniae (No. 1 test), illustrate that Herba Diclipterae Chinensis and Herba Houttuyniae unite the effect that use has Synergistic really.Wherein, when the raw medicinal material weight percentage is: Herba Diclipterae Chinensis 50%-90%, during Herba Houttuyniae 10%-50%, pharmacological action is better; When the raw medicinal material weight percentage is: Herba Diclipterae Chinensis 60%-70%, during Herba Houttuyniae 30%-40%, pharmacological action is better.
In further pharmacological evaluation, research worker of the present invention is found, when the raw medicinal material weight percentage is: Herba Diclipterae Chinensis 62.5%, Herba Houttuyniae 37.5%, promptly when the ratio of Herba Diclipterae Chinensis and Herba Houttuyniae was 5: 3, therapeutic effect was best.
The specific embodiment
Further describe the present invention with embodiment below, help understanding, but described embodiment only is used to illustrate the present invention rather than restriction the present invention the present invention and advantage thereof, better effects if.
Effect experiment: according to the medicine of the method in application number CN03160036.0 patent documentation preparation as positive control drug.With commercially available Herba Diclipterae Chinensis, Herba Houttuyniae medical material, according to the invention described above method preparation cost invention pharmaceutical preparation.With preceding said medicine all is mixed with same concentrations.
Bacteriostatic experiment: the antibacterial culturing beef-protein medium, mycete is cultivated and uses the Cha Shi culture medium, and culture medium must be at 1.05kg/cm
2, the sterilization 20 minutes; For the examination strain escherichia coli, staphylococcus aureus, bacillus subtilis are arranged; 37 ℃ of cultivations of escherichia coli 24 hours, staphylococcus aureus and bacillus subtilis are cultivated after 24 hours for 30～32 ℃, measure the antibacterial circle diameter size, determine fungistatic effect.The results are shown in Table 2.
Table 2 bacteriostatic experiment result
| Group | Antibacterial circle diameter (mm) | ||
| Escherichia coli | Staphylococcus aureus | Bacillus subtilis | |
| Positive controls pharmaceutical preparation group of the present invention | 9.6 12.4 | 15.5 20.8 | 8.4 11.0 |
The antiinflammatory experiment: xylol causes the inhibitory action of mice ear
Get 30 of healthy Kunming mouses, body weight 20～24g.Be divided into normal control group, positive controls, pharmaceutical preparation group of the present invention at random.Every group 10, male and female half and half, sub-cage rearing.The dosage of positive controls and pharmaceutical preparation group of the present invention is 5g crude drug/kg; Oral administration, the normal control group gives isopyknic distilled water, successive administration 5 days, after last 1 administration 30 minutes, two sided coatings dimethylbenzene 0.03ml causes inflammation before and after every mice left side ear, animal is put to death in the cervical vertebra dislocation after 30 minutes, cut two ears along the auricle baseline, lay round auricle at same antimere respectively with 9mm diameter card punch, torsion balance is weighed, the left auricle of every Mus heavily deducts auris dextra sheet weight and is the swelling degree, calculate average and the standard deviation of respectively organizing the swelling degree, and do the t check, the comparable group differences calculates swelling by following formula and suppresses percentage rate: suppression ratio=(the average swelling degree of the matched group-average swelling degree of administration the group)/average swelling degree of matched group * 100%.The results are shown in Table 3.
Table 3 xylol causes the inhibitory action (X ± S) of mice ear
| Group | Mus number (only) | Ear swelling rate (%) | Suppression ratio (%) |
| Normal control group positive controls pharmaceutical preparation group of the present invention | 10 10 10 | 13.56±2.76 10.85±2.48 ** 9.30±3.22 **# | - 20.0 31.4 |
Annotate: compare with the normal control group:
*P＜0.05,
*P＜0.01; Compare with positive controls: #P＜0.05
The antiviral experiment: 60 of cleaning level Kunming kind healthy mices, body weight 18～22g, male and female half and half are divided into 3 groups at random, i.e. normal control group, positive controls, pharmaceutical preparation group of the present invention.The dosage of positive controls and pharmaceutical preparation group of the present invention is 5g crude drug/kg; Oral administration, the normal control group gives isopyknic distilled water.In infective virus beginning in preceding 1 day administration, every day 1 time, continuous 5 days.Under the ether light anaesthesia, collunarium infects RSV liquid 0.05ml/ that 10 sesquialters are counted infective dose.Dissected mice collection respiratory tract washing liquid in 24 hours after the last administration, 96 orifice plates of cell monolayer have been covered with in inoculation, put CO
2Cultivate after 30 days for 37 ℃ in the incubator, observation of cell changes, the infection rate of each group of counting.Experimental result sees Table 4.
Table 4 antiviral experimental result
| Group | Mus number (only) | Infect number (only) | Infection rate (%) |
| Normal control group positive controls pharmaceutical preparation group of the present invention | 20 20 20 | 16 10 6 | 80 50 ** 30 **# |
Annotate: compare with the normal control group:
*P＜0.05,
*P＜0.01; Compare with positive controls: #P＜0.05
By above experiment as can be seen, pharmaceutical composition of the present invention has well antibacterial, antiinflammatory, antivirus action.
Preparation embodiment
Embodiment 1
Herba Diclipterae Chinensis 1000g Herba Houttuyniae 600g
With above-mentioned pulverizing medicinal materials, soaked 2 hours, steam distillation 6 hours gets extract A; With water boiling and extraction 1 time, merge extractive liquid, filters with medicinal residues, and filtrate decompression is concentrated into the 1/4-1/2 that is equivalent to the raw medicinal herbs amount, under agitation adds ethanol and makes and contain the alcohol amount and reach 90%, leaves standstill, filter, the filtrate concentrate drying, extract B; With extract A,, get extract B again with the dissolving of 20ml Polysorbate, the water for injection 800ml that adds prepared fresh stirs and makes dissolving, and the water for injection that adds new system is again regulated pH value to 6.0-7.0 to 1000ml, autoclaving adds active carbon 0.5g, stirs evenly, keep little and boiled 15 minutes, filter while hot, filtrate filters with the microporous filter membrane of 0.22 μ m again, embedding, 500 injection are made in sterilization, promptly get injection of the present invention.
Embodiment 2
Herba Diclipterae Chinensis 1000g Herba Houttuyniae 800g
With above-mentioned pulverizing medicinal materials, carry out supercritical fluid extraction, pressure is controlled to be 30Mpa, 50 ℃ of temperature, cycling extraction 4 hours gets extract A; With water boiling and extraction 2 times, merge extractive liquid, filters with medicinal residues, and filtrate decompression is concentrated into the 1/4-1/2 that is equivalent to the raw medicinal herbs amount, under agitation adds ethanol and makes and contain the alcohol amount and reach 50%, leaves standstill, filter, the filtrate concentrate drying, extract B; Extract B is pulverized, added starch 100g, granulate, drying sprays into extract A, adds low-substituted hydroxypropyl cellulose 20g, carboxymethyl starch sodium 15g again, and magnesium stearate 2g makes 1000, and the bag film-coat promptly gets tablet of the present invention.
Embodiment 3
Herba Diclipterae Chinensis 1000g Herba Houttuyniae 500g
With above-mentioned pulverizing medicinal materials, soaked 2 hours, steam distillation 4 hours gets extract A; With water boiling and extraction 2 times, merge extractive liquid, filters with medicinal residues, and filtrate decompression is concentrated into the 1/4-1/2 that is equivalent to the raw medicinal herbs amount, under agitation adds ethanol and makes and contain the alcohol amount and reach 70%, leaves standstill, filter, the filtrate concentrate drying, extract B; Get extract B is pulverized, spray into extract A, add starch 50g, micropowder silica gel 5g makes 1000 capsules, promptly gets capsule of the present invention.
Embodiment 4
Herba Diclipterae Chinensis 1000g Herba Houttuyniae 500g
With above-mentioned pulverizing medicinal materials, carry out supercritical fluid extraction, pressure is controlled to be 10Mpa, 20 ℃ of temperature, cycling extraction 2 hours gets extract A; With water boiling and extraction 2 times, merge extractive liquid, filters with above-mentioned medicinal residues, and filtrate decompression is concentrated into the 1/4-1/2 that is equivalent to the raw medicinal herbs amount, under agitation adds ethanol and makes and contain the alcohol amount and reach 60%, leaves standstill, filter, the filtrate concentrate drying, extract B; Get extract B, pulverize, add the cane sugar powder of 2 times of amounts respectively, the dextrin of 1 times of amount is made granule, sprays into extract A, makes 1000 bags, promptly gets granule of the present invention.
Embodiment 5
Herba Diclipterae Chinensis 1000g Herba Houttuyniae 600g
With above-mentioned pulverizing medicinal materials, soaked 2 hours, steam distillation 5 hours gets extract A; Get extract A,, join in the aqueous solution of saturated hydroxypropyl of 10 times of amounts, stirred 4 hours, put to place in the refrigerator and spend the night, filter, get the precipitation cold drying with small amount of ethanol dissolving, must the hydroxypropyl clathrate.With water boiling and extraction 2 times, merge extractive liquid, filters with medicinal residues, and filtrate decompression is concentrated into the 1/4-1/2 that is equivalent to the raw medicinal herbs amount, under agitation adds ethanol and makes and contain the alcohol amount and reach 80%, leaves standstill, filter, the filtrate concentrate drying, extract B; Get the hydroxypropyl clathrate, get extract B again, add injection water 800ml stirring and make dissolving, add mannitol 60g, add the injection water, regulate pH value to 6.0-7.0 to 1000ml, add active carbon 0.5g, stir evenly, keep little and boiled 15 minutes, filter while hot, filtrate is utilized 105 ℃ of sterilizations of circulation steam 30 minutes, and the microporous filter membrane with 0.22 μ m filters again, pour into cillin bottle, lid is rolled in lyophilization, make 500 bottles, promptly get lyophilized injectable powder of the present invention.
The test example
The following experiment of research worker design of the present invention is to observe pharmaceutical composition of the present invention (embodiment 1 described injection) for treatment of conditions effects such as viral influenza, upper respiratory tract infection, mumps, pneumonia.Wherein all design object of study, research method, diagnostic criteria, experiment case standard, observation index, curative effect judging standard, the course of treatment according to the comparative example in the patent application document of application number CN03160036.0, medication is: all intramuscular injection of pharmaceutical preparation group of the present invention and positive controls (commercially available Herba Houttuyniae injectio), a 2ml, 2 times on the one.The observation therapeutic effect is as follows:
Therapeutic effect to influenza: pharmaceutical preparation group total effective rate of the present invention is 92%, and positive controls is 71%.
Therapeutic effect to last sense: pharmaceutical preparation group total effective rate of the present invention is 88%, and positive controls is 70%.
The improvement of popularity parotitis clinical symptoms: pharmaceutical preparation group total effective rate of the present invention is 100%, and positive controls is 90%.
Improvement to the pneumonia clinical symptoms: pharmaceutical preparation group total effective rate of the present invention is 86%, and positive controls is 54%.
Toxic and side effects is observed: all case has all been done the heart, kidney, liver function and whole blood routine examination before and after treatment, finds no any abnormal change.And the patient infected the leucocytes reduction caused and all returned to normally in that sb.'s illness took a favorable turn and cure the back leukocyte.
In treatment group and matched group, when removing accidental individual patient intramuscular injection, medicine-feeding part pain or occur outside the drug eruption is not seen other untoward reaction.
By above-mentioned clinical experimental data as can be seen, pharmaceutical preparation of the present invention has good therapeutical effect for diseases such as viral influenza, upper respiratory tract infection, mumps, pneumonia, and therapeutic effect is significantly better than the contrast medicine.
Claims (7)
1, a kind of pharmaceutical composition with bacteria-inhibiting anti-inflammation function is characterized in that, the raw medicinal material weight percentage of pharmaceutical composition is: Herba Diclipterae Chinensis 50%-90%, Herba Houttuyniae 10%-50%.
2, pharmaceutical composition according to claim 1 is characterized in that, the raw medicinal material weight percentage of pharmaceutical composition is: Herba Diclipterae Chinensis 60%-70%, Herba Houttuyniae 30%-40%.
3, pharmaceutical composition according to claim 1 is characterized in that, the raw medicinal material weight percentage of pharmaceutical composition is: Herba Diclipterae Chinensis 62.5%, Herba Houttuyniae 37.5%.
4, want profit to require the described pharmaceutical composition of one of 1-3 according to right, it is characterized in that pharmaceutical composition can be prepared into tablet, capsule, granule, oral liquid, injection with small volume, high-capacity injection, injectable powder or freeze-dried powder.
5, the described preparation of drug combination method of one of claim 1-3 is characterized in that, may further comprise the steps:
(1) Herba Diclipterae Chinensis, Herba Houttuyniae are pulverized, adopted steam distillation or supercritical liquid extraction technique to extract, get extract A;
(2) with above-mentioned medicinal residues with water boiling and extraction 1-2 time, merge extractive liquid, filters, filtrate decompression is concentrated into the 1/4-1/2 that is equivalent to the raw medicinal herbs amount, under agitation adds ethanol and makes and contain the alcohol amount and reach 50%-90%, leaves standstill, and filters, the filtrate concentrate drying gets extract B.
(3) extract A and extract B are merged, add the corresponding medicinal adjuvant, make corresponding preparation.
6, preparation method according to claim 5 is characterized in that, the concrete steps of described water vapour distillation are: after pulverizing medicinal materials, soaked steam distillation 4-6 hour 2 hours; The concrete steps of described supercritical fluid extraction are: pressure is controlled to be 10-30MPa, 30 ℃-50 ℃ of temperature, cycling extraction 2-4 hour.
7, the application of the described pharmaceutical composition of one of claim 1-3 in preparation treatment viral influenza, upper respiratory tract infection, mumps, pneumonia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510123618 CN1775242A (en) | 2005-11-18 | 2005-11-18 | Medicine composition with bacteria-inhibiting anti-inflammation function, its preparing method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510123618 CN1775242A (en) | 2005-11-18 | 2005-11-18 | Medicine composition with bacteria-inhibiting anti-inflammation function, its preparing method and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1775242A true CN1775242A (en) | 2006-05-24 |
Family
ID=36765041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510123618 Pending CN1775242A (en) | 2005-11-18 | 2005-11-18 | Medicine composition with bacteria-inhibiting anti-inflammation function, its preparing method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1775242A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587035A (en) * | 2015-03-03 | 2015-05-06 | 张远强 | Medicine composition for treating oral ulcer and preparation method for medicine composition |
| CN109350671A (en) * | 2018-11-13 | 2019-02-19 | 禹州市中医院 | It is a kind of for treating the compound Houttuynia cordata injection of tympanitis |
-
2005
- 2005-11-18 CN CN 200510123618 patent/CN1775242A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587035A (en) * | 2015-03-03 | 2015-05-06 | 张远强 | Medicine composition for treating oral ulcer and preparation method for medicine composition |
| CN109350671A (en) * | 2018-11-13 | 2019-02-19 | 禹州市中医院 | It is a kind of for treating the compound Houttuynia cordata injection of tympanitis |
| CN109350671B (en) * | 2018-11-13 | 2021-04-06 | 禹州市中医院 | Compound houttuynia cordata injection for treating otitis media |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101152324A (en) | Method for producing Yujin composition and medicament containing the same | |
| CN102961469B (en) | Traditional Chinese medicine dispersible tablet for treating upper respiratory infection, and preparation method and quality detection method thereof | |
| CN1730015A (en) | Honey suckle extract and its preparing process and application | |
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN102688332A (en) | Traditional Chinese medicine composition for treating cold and preparation method thereof | |
| CN101322810B (en) | Chinese traditional medicine composition for treating diabetes respiratory tract infection | |
| CN102716223A (en) | Chinese medicinal composition for treating upper respiratory tract infection and preparation method thereof | |
| CN102641323B (en) | Application of Gueldenstaedtia delavayi Franch or extracts thereof | |
| CN1221277C (en) | Prophylaxis medication for treating pneumonia, bronchitis, pharyngitis and upper respiratory tract infection as well as its preparing method | |
| CN1857416A (en) | Chinese medicine composition with functions of expelling surficial evils and clearing away head and toxic materials and its preparing method and application | |
| CN1785384A (en) | Chinese medicinal composition for treating tuberculosis and its preparation method | |
| CN1775242A (en) | Medicine composition with bacteria-inhibiting anti-inflammation function, its preparing method and use | |
| CN1259929C (en) | Anti-virus medicine | |
| CN1748736A (en) | New medicine administration path for reducing heat and detoxicating injection an dits preparing process | |
| CN100542578C (en) | The extract and the extracting method of the combined traditional Chinese medicine material of treatment respiratory system disease | |
| CN103816281B (en) | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold | |
| CN102908397A (en) | Chinese herbal compound for treating wind-heat type common cold by dredging surfaces and releasing muscles and preparation thereof | |
| CN1289124C (en) | Medicine for treating child common cold and its preparation method | |
| CN102379958A (en) | Chinese medicinal preparation for resisting bacteria, diminishing inflammation, eliminating phlegm and relieving cough and preparation method thereof | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN1823859A (en) | Medicinal composition containing dicliptera volatile oil, its preparation method and use | |
| CN1730014A (en) | Novel drug administration route of semen armeniacae amarum injection, its preparation process and new indications | |
| CN1931229B (en) | Medicine for treating acute and chronic nasopharyngitis and its preparation process | |
| CN107095977A (en) | A kind of medicament and its pharmaceutical formulation and preparation method with the malicious effect of fire row of dispelling | |
| CN1799612A (en) | Novel drug administering route of 'Qu Gan Re' injection, its preparation process and novel indications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20081107 Address after: One hundred and thirty-five thousand No. 66, Xiangjiang Road, Meihekou, Jilin, Postal Code: 135000 Applicant after: Duprofit Pharmacy Company Limited Address before: Eastern section of North Ring Road, Meihekou, Jilin Applicant before: Lokis Pharmaceutical (Jilin) Group Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: KYORIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ACTIVX BIOSCIENCES INC. Effective date: 20101027 Free format text: FORMER OWNER: KYORIN PHARMACEUTICAL CO., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: CALIFORNIA STATE, UNITED STATES TO: TOKYO, JAPAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20101105 Address after: 135000 Meihekou province Jilin City Beihuan Road No. 1666 Applicant after: Boan Brothers Holding Limited Address before: 135000 No. 66, Xiangjiang Road, Meihekou, Jilin Applicant before: Duprofit Pharmacy Company Limited |
|
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20060524 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |